Building blocks of life
Proteins that self-assemble into supramolecular complexes
A collaborative research team based in Japan has designed new proteins that can self-assemble into the complex structures underlying biological organisms, laying the groundwork for leading-edge applications in biotechnology.

The design of novel proteins that self-assemble into supramolecular complexes is important for development in nanobiotechnology and synthetic biology.
2018, American Chemical Society
The researchers created and developed the proteins with a specific function and their method reveals a possibility that certain protein functions can be created on demand.
The scientists published their results on April 24th in Synthetic Biology, a peer-reviewed journal published by the American Chemical Society (ACS).
"All organisms contain self-assembling biomolecules including proteins, nucleic acids, sugars, and lipids," wrote Ryoichi Arai in the paper he authored. Arai is the head of the department of supramolecular complexes in the Research Center for Fungal and Microbial Dynamism at Shinshu University in Japan. "The ability to design and control such assemblies is a central goal of biomolecular engineering, nanobiotechnology, and synthetic biology."
Arai and his team developed a simple and stable artificial protein, called WA20, in 2012. By 2015, the researchers progressed to Protein Nanobuilding Blocks (PN-Blocks), which use WA20 to self-assemble into multiple nanostructures.
The researchers built on that success to develop extender PN-Blocks, which link WA20 proteins together to produce chain-like protein complexes and even more nanostructures.
"The design and construction of self-assembling PN-Blocks is a useful strategy--they're like LEGO blocks," Arai said, referring to the plastic toy blocks that can be built into vastly different structures despite how little they individually vary.
The scientists linked two WA20 proteins in tandem (ePN-Block), creating oligomeric structures. Another PN-Block (sPN-Block) intervened, affecting the structures to be different, varied chain-like complexes on demand. Getting these complexes together, the supramolecular nanostructure complexes were achieved by introducing a metal ion, which triggered the process through further self-assembly.
The researchers plan to create a variety of stable and functional complex nanostructures through the combination of various PN-Blocks. The potential of PN-Blocks has been increased even more now that more complexes can evolve with the help of metal ions.
"These results demonstrate that the PN-Block strategy is a useful and systematic strategy for constructing novel nano-architectures," Arai said, noting that the ability to construct novel complexes is particularly important in biotechnology and synthetic biology.
The next step is for the researchers to further develop nanostructures to contribute to the development of nanobiomaterials, which could be used as a drug delivery system or to create useful proteins for the bio-pharmaceutical investigation, such as artificial vaccine in an environmental friendly way.
Original publication
Naoya Kobayashi, Kouichi Inano, Kenji Sasahara, Takaaki Sato, Keisuke Miyazawa, Takeshi Fukuma, Michael H Hecht, Chihong Song, Kazuyoshi Murata, and Ryoichi Arai; "Self-Assembling Supramolecular Nanostructures Constructed from de Novo Extender Protein Nanobuilding Blocks"; ACS Synthetic Biology; 2018
Original publication
Naoya Kobayashi, Kouichi Inano, Kenji Sasahara, Takaaki Sato, Keisuke Miyazawa, Takeshi Fukuma, Michael H Hecht, Chihong Song, Kazuyoshi Murata, and Ryoichi Arai; "Self-Assembling Supramolecular Nanostructures Constructed from de Novo Extender Protein Nanobuilding Blocks"; ACS Synthetic Biology; 2018
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Kainate_receptor
Neocortex
Ventricular_tachycardia
Familial_adenomatous_polyposis
Adrenal_tumor
Dipsogen
Learning_problems_in_childhood_cancer
Inflammation

Can quantum computers help in the development of new drugs? - The possibilities of this technology have been investigated by the University of Vienna, Boehringer Ingelheim, BASF, Google, QC Ware and the University of Toronto
Exoribonuclease
GC-content
